Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 4,400 shares of the firm’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $13.54, for a total value of $59,576.00. Following the completion of the transaction, the chief executive officer now owns 737,767 shares of the company’s stock, valued at approximately $9,989,365.18. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) traded up 0.36% during mid-day trading on Friday, hitting $13.85. The company’s stock had a trading volume of 98,634 shares. The company’s market cap is $423.24 million. Atara Biotherapeutics, Inc. has a 12-month low of $11.80 and a 12-month high of $23.00. The firm’s 50-day moving average is $14.82 and its 200-day moving average is $15.90.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by $0.05. Analysts predict that Atara Biotherapeutics, Inc. will post ($3.89) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Atara Biotherapeutics, Inc. (ATRA) CEO Sells $59,576.00 in Stock” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://theolympiareport.com/2017/08/27/insider-selling-atara-biotherapeutics-inc-atra-ceo-sells-59576-00-in-stock.html.

Large investors have recently made changes to their positions in the stock. Redmile Group LLC boosted its stake in shares of Atara Biotherapeutics by 2.4% in the first quarter. Redmile Group LLC now owns 2,734,118 shares of the biotechnology company’s stock worth $56,186,000 after buying an additional 63,176 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Atara Biotherapeutics by 617.9% in the first quarter. Goldman Sachs Group Inc. now owns 201,214 shares of the biotechnology company’s stock worth $4,135,000 after buying an additional 173,184 shares during the last quarter. American International Group Inc. boosted its stake in shares of Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after buying an additional 948 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Atara Biotherapeutics during the first quarter worth approximately $132,000. Finally, Vident Investment Advisory LLC boosted its stake in shares of Atara Biotherapeutics by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 55,665 shares of the biotechnology company’s stock worth $1,144,000 after buying an additional 9,276 shares during the last quarter. 78.21% of the stock is owned by institutional investors and hedge funds.

A number of research firms have recently commented on ATRA. BidaskClub cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Canaccord Genuity set a $47.00 price objective on Atara Biotherapeutics and gave the company a “buy” rating in a research report on Monday, August 7th. ValuEngine lowered Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $30.00 price objective on shares of Atara Biotherapeutics in a research report on Thursday, June 22nd. Four investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $23.60.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.